Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer - Wikidata - awgldk - TriplyDB

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

http://www.wikidata.org/entity/Q24202975

about

Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells.

P2860

Q26858830-F7D86564-23AA-4117-8651-4623A1CF12A4 Q37108536-D7D1C579-53FD-4B1F-B825-D00B26853446 Q48310595-90785C69-8EC8-4FF8-B420-6DADEF3B8B08

P2860

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

http://www.wikidata.org/entity/Q24202975

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@ast

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en-gb

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@nl

type

label

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@ast

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en-gb

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@nl

prefLabel

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@ast

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en-gb

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@nl

P1433

Q24202975-B3FFB2C3-3BE5-4F13-8539-6AA34231C83D

P1476

Q24202975-BB345DF8-3735-4963-B8FF-D71A3FF6627F

P2093

Q24202975-4E4BBCF4-64DE-44AF-98E0-990E8D9E7DD9

P2860

Q24202975-061EF0AE-8DA5-4CD3-B741-4B6691299EE7

Q24202975-19C34C86-6FCF-4F92-B7B0-FD4D7E80CC07

Q24202975-26418962-425F-46B8-80E4-6A499CEA921C

Q24202975-43966780-AA71-4A68-B83B-837B8E346976

Q24202975-509D63FE-D6CC-4AE8-A716-1EAF20D13371

Q24202975-5225851D-6A00-44F6-BC96-7BADAC75A052

Q24202975-52CCB777-597C-49EA-A959-A30F1F4D1748

Q24202975-57BED82B-9F83-4007-8282-66B0E3DC585B

Q24202975-7DAD21E5-45C1-431D-B2CB-21B6B4DA3686

Q24202975-7FE1A471-AD40-4283-9A12-21E18B52814B

P304

Q24202975-A6F79C88-C8B6-473D-B0B4-1E451C7F90AA

P31

Q24202975-DD5B24E8-FA7E-4022-A332-A81337B0EF72

Q24202975-bb925415-17f0-49c1-a82a-b3ba5f6b96d1

P3181

Q24202975-149B1AF7-AC45-4913-912A-90F7A4730862

P356

Q24202975-26E22EDD-B4AD-4D25-A47F-17C5B82FC90F

P433

Q24202975-67C69F28-7155-46ED-B455-09F3326BCB0E

P50

Q24202975-05079892-1F93-4573-9015-2DE6E8BAE9DD

Q24202975-720C1D7A-6648-4EBD-92D9-E3761E88DD62

Q24202975-F870D02A-18D7-4B1F-8705-E6B547137449

P577

Q24202975-9FE38864-3A9B-4023-AE87-FCBFE5FACA44

P698

Q24202975-EB9A72AB-A83A-42DE-A5EC-561B45CA99DA

P921

Q24202975-47D6B46E-3590-43EA-A6EA-9987B86A88A5

P932

Q24202975-37C2E853-A706-454E-9547-B01899A98414

P3181

P356

14651858.CD010482.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

@en

P2093

Clemens Thoma

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

A phase 3 trial of bevacizumab in ovarian cancer.

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia.

P304

CD010482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

785345

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD010482.PUB2

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P50

Theresa A Lawrie

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24142521

http://www.w3.org/2001/XMLSchema#string

P921

P932

6457824

http://www.w3.org/2001/XMLSchema#string